Caplin Point Laboratories Q1 FY26 – Latin America’s Favorite Chemist Expands, US FDA Approvals Raining, Margins Still as Juicy as Mango Season
1. At a Glance
Caplin Point just served a pharma cocktail that’s stronger than Old Monk in Q1 FY26: revenue ₹533 crore (+11.7% YoY), PAT ₹151 crore (+20.7% YoY), and OPM ~34%. With 82% of sales from Latin America and FDA approvals flying in monthly like Amazon Prime packages, this Chennai-based underdog has quietly turned into a ₹17,700 crore market-cap beast. But P/E at ~31x means markets already priced in half of Mexico and Brazil.
2. Introduction
Imagine a desi company that decided “Why fight Dr Reddy’s in Hyderabad when we can sell antibiotics in Honduras?” That’s Caplin Point for you—a pharma player that went where others didn’t bother, building dominance in Latin America’s dusty towns while Big Pharma was busy chasing the US and Europe.
Now, Caplin is back to the US party through its subsidiary Caplin Steriles. With 25 ANDA approvals, 14 more under review, and distribution licenses in 49 US states, it’s suddenly behaving like that quiet kid in class who now runs a startup in California.
The funny bit? They do all this while being asset-light—outsourcing 45% to India & China partners. Think of it as Swiggy for pharma: they control the menu, brand, and delivery, but someone else does the cooking.
3. Business Model – WTF Do They Even Do?
Caplin’s revenue pie looks like this:
Generics (75%): Plain vanilla tablets, injections, and pills.
Branded Generics (25%): Fancy packaging, better margins, local doctor tie-ups.
Geography: 82% Latin America, 18% rest (Africa, US, others).
Product range? Over 650 formulations, 4,000 licenses, covering everything from eye drops to suppositories (yes, that too). Their R&D team of 385 is working on injectables, APIs, biologics, and biosimilars.
Basically: Caplin is the chemist who sells both Crocin for your headache and the syringe that gives you anesthesia.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
₹533 Cr
₹477 Cr
₹510 Cr
+11.7%
+4.5%
EBITDA
₹178 Cr
₹152 Cr
₹168 Cr
+17.1%
+6.0%
PAT
₹151 Cr
₹125 Cr
₹145 Cr
+20.7%
+4.1%
EPS (₹)
20.1
16.3
18.8
+23.3%
+6.9%
Annualised EPS = ~₹80.5 → P/E ~28.9x at CMP ₹2,330
Commentary: While most pharma cos cry about USFDA issues, Caplin’s profits are compounding like SIP returns. Margins at 33–34% OPM are fatter than a mithai shop’s ghee account.
5. Valuation Discussion – Fair Value Range
P/E Method: EPS TTM = ₹74.4. Industry P/E = 33.8. Range = 74.4 × (25–35) = ₹1,860 – ₹2,600.
